News|Articles|November 16, 2026

Maternal autoantibodies linked to autism subtype, recurrence risk

Key Takeaways

  • Data presented at NSGC 2026 link specific maternal autoantibody combinations, identified in CHARGE and confirmed in MARBLES, to a non-genetic autism subtype with high sibling recurrence risk; sample sizes and effect estimates were not disclosed.
  • Younger siblings of autistic children have a recurrence rate of about 20%, so close surveillance and prompt referral remain essential regardless of maternal testing.
SHOW MORE

Data presented at NSGC 2026 tie maternal autoantibody combinations to a non-genetic autism subtype with high recurrence risk in later-born siblings.

Specific combinations of maternal autoantibodies may identify a non-genetic form of autism that carries a high risk of recurrence in younger siblings, according to findings from MARAbio presented at the National Society of Genetic Counselors (NSGC) 45th Annual Conference, held November 10-14, 2026, in Baltimore, Maryland.¹ The company said the results could inform recurrence-risk counseling and earlier evaluation.¹

"While genetic testing has advanced our understanding of autism, these findings highlight an important non-genetic contributor," said E. Robert Wassman, MD, a board-certified medical geneticist and chief medical officer of MARAbio, who added that the findings can help clinicians offer families more individualized counseling.¹

Maternal autoantibody findings from the CHARGE and MARBLES autism cohorts

Megan Martin, MS, CGC, vice president of operations at MARAbio, presented the analysis, which examined maternal blood samples from 2 research cohorts: the Childhood Autism Risks from Genetics and the Environment (CHARGE) study and the Markers of Autism Risk in Babies–Learning Early Signs (MARBLES) study.¹ Autoantibody combinations first identified in CHARGE were confirmed in MARBLES, and these combinations were associated with a distinct, non-genetic form of autism and a high risk of recurrence in subsequent children.¹

The announcement did not report sample sizes, the specific autoantibody combinations analyzed, or a quantified recurrence risk, and the data have not yet appeared in a peer-reviewed publication.¹

What is maternal autoantibody-related autism (MARA)?

In MARA, maternal autoantibodies are thought to cross the placenta and target proteins involved in fetal brain development.¹ The company estimates that MARA accounts for approximately 10% to 20% of autism cases and notes that studies have linked it to more severe symptoms and, in some cases, co-occurring intellectual disability.¹

Earlier peer-reviewed work outlines the biomarker approach. In a 2021 study in Molecular Psychiatry, investigators tested plasma from 450 mothers of children with autism and 342 mothers of typically developing children for reactivity to 8 fetal brain proteins, including CRMP1, CRMP2, GDA, NSE, and STIP1.² Autism-specific reactivity patterns were found in 18% of the training set and 10% of the validation set, compared with 0% of controls.² The most common pattern, CRMP1 plus GDA, appeared in 4.2% of mothers of autistic children (OR, 31.04), and reactivity to CRMP1 was associated with higher Autism Diagnostic Observation Schedule severity scores (OR, 2.3; 95% CI, 1.36-3.99).²

Autism recurrence risk in siblings and genetic counseling

Recurrence counseling currently relies largely on empirical estimates. In a 2024 Baby Siblings Research Consortium analysis of 1605 infants with an older autistic sibling followed to age 3 years at 18 sites, 20.2% received an autism diagnosis.³ Male sex and having more than 1 affected older sibling were significant predictors of recurrence, and the authors recommended close monitoring and prompt referral for these younger siblings.³

MAR-Autism test performance and intended use

MARAbio markets the MAR-Autism Test, a maternal blood test designed to detect MARA-associated autoantibodies.¹ It is intended for mothers of children who have been diagnosed with or show signs of autism, is meant to complement clinical assessment, and is not validated for use during pregnancy.¹ Clinical validation results the company presented in October reported 99.8% specificity and a 97.5% positive predictive value in a high-risk population.¹ A separate analytical validation study, published in Diagnostics in 2026 and coauthored by MARAbio investigators, reported that the test's 8 component enzyme-linked immunosorbent assays met predefined performance criteria.⁴

"Our focus is on translating this scientific progress into meaningful clinical information for families," said Michael Paul, chief executive officer of MARAbio.¹

References
1. MARAbio presents new clinical findings linking maternal autoantibodies to a non-genetic form of autism and high familial recurrence risk. News release. MARAbio Systems; November 16, 2026. Accessed November 16, 2026. https://www.prnewswire.com/news-releases/marabio-presents-new-clinical-findings-linking-maternal-autoantibodies-to-a-non-genetic-form-of-autism-and-high-familial-recurrence-risk-302939398.html
2. Ramirez-Celis A, Becker M, Nuño M, Schauer J, Aghaeepour N, Van de Water J. Risk assessment analysis for maternal autoantibody-related autism (MAR-ASD): a subtype of autism. Mol Psychiatry. 2021;26(5):1551-1560. doi:10.1038/s41380-020-00998-8
3. Ozonoff S, Young GS, Bradshaw J, et al. Familial recurrence of autism: updates from the Baby Siblings Research Consortium. Pediatrics. 2024;154(2):e2023065297. doi:10.1542/peds.2023-065297
4. McInerney M, Hurley B, Barkow J, et al. Analytical validation of an ELISA assay for maternal autoantibody-related autism. Diagnostics (Basel). 2026;16(11):1665. doi:10.3390/diagnostics16111665

Related to this article

Is it withdrawal or relapse?
In this teaching case, an 18-year-old develops severe anxiety 2 months after stopping long-term fluoxetine because of hyperprolactinemia, raising the question of whether her symptoms reflect antidepressant withdrawal or relapse.